Amerise Biosciences Reports Net Loss in Q1 FY2026 Amid Revenue Decline
Amerise Biosciences Limited, an Ahmedabad-based biosciences company, reported a net loss of Rs. 0.81 lacs for Q1 FY2026, ending June 30, 2025. This marks a significant shift from the previous quarter's profit of Rs. 10.59 lacs. Total income decreased to Rs. 6.37 lacs from Rs. 18.80 lacs in the preceding quarter. The company's revenue came entirely from other operating revenue, with no gross revenue from product sales. Total expenses were Rs. 7.18 lacs, mainly comprising employee benefit expenses and other expenses. The Board of Directors approved these unaudited financial results on July 24, 2025, which were reviewed by the Audit Committee and auditors.
*this image is generated using AI for illustrative purposes only.
Amerise Biosciences Limited, a biosciences company based in Ahmedabad, has reported a net loss for the first quarter of the fiscal year 2026, as revealed in its latest financial results.
Financial Performance
The company reported a net loss of Rs. 0.81 lacs for the quarter ended June 30, 2025, a significant shift from the profit of Rs. 10.59 lacs recorded in the previous quarter. This downturn in financial performance was accompanied by a substantial decline in total income, which fell to Rs. 6.37 lacs from Rs. 18.80 lacs in the preceding quarter.
Revenue Breakdown
Interestingly, Amerise Biosciences' revenue for the quarter came entirely from other operating revenue, with no gross revenue reported from product sales. This suggests a potential shift in the company's revenue streams or operational focus.
Expenses
Total expenses for the quarter stood at Rs. 7.18 lacs, primarily consisting of:
- Employee benefit expenses: Rs. 2.32 lacs
- Other expenses: Rs. 4.86 lacs
Key Financial Metrics
| Particulars | Q1 FY2026 (Rs. in lacs) | Q4 FY2025 (Rs. in lacs) |
|---|---|---|
| Total Income | 6.37 | 18.80 |
| Total Expenses | 7.18 | 8.21 |
| Net Profit/(Loss) | (0.81) | 10.59 |
| EPS (Basic & Diluted) | (0.00) | 0.02 |
The company's paid-up equity share capital remained constant at Rs. 660.69 lacs.
Board Meeting and Auditor's Review
As per the LODR data, the Board of Directors of Amerise Biosciences Limited met on July 24, 2025, to consider and approve the unaudited financial results for the quarter ended June 30, 2025. The meeting commenced at 03:50 PM and concluded at 04:15 PM.
The financial results have been reviewed by the Audit Committee and approved by the Board of Directors. Additionally, the statutory auditors, BIPIN & CO. Chartered Accountants, have carried out a limited review of the financial results, as required by SEBI regulations.
Outlook
While the company has faced a challenging quarter with decreased revenue and a shift to a net loss position, it's important to note that quarterly results can be subject to various factors and may not necessarily indicate long-term trends. Investors and stakeholders will likely be watching closely to see how Amerise Biosciences navigates these challenges in the coming quarters.
Note: All financial figures are in Indian Rupees (Rs.) and are reported in lacs.
Historical Stock Returns for Amerise Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -7.35% | +6.78% | +14.55% | -24.10% | -31.52% | -28.41% |
17
